Skip to main content
Patient portrayal of a woman

A gene mutation may throw you off course

Some patients with Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase can develop what’s known as a gene mutation. A mutation is a change in the DNA of a cell.

Icon of gene mutation

Mutations may cause drug resistance

 

One of the goals of treatment for Ph+ CML in chronic phase is to see the number of leukemic cells in the blood go down. That may not happen for some people.

If the number of leukemic cells in your body starts going up instead of decreasing, your doctor may want to see if you have become resistant to your medication. This is often called “drug resistance.” It occurs when cancer cells are not responding to a medication.

 

There are 2 types of drug resistance:

 

  • Lack of response, also called primary drug resistance: The body does not respond to a medication

  • Secondary drug resistance: Over time, the body stops responding to a medication

 

Learn how SCEMBLIX may help

Testing for a mutation in the BCR‑ABL1 gene

In Ph+ CML in chronic phase, one of the causes of drug resistance is a mutation in the BCR‑ABL1 gene.
Here are some reasons why your doctor may decide to have you tested for a gene mutation:

  • You are not responding or are no longer responding to a medication

  • You are unable to reach a treatment milestone

To determine if you have a mutation, your doctor may order a BCR‑ABL1 kinase domain mutation analysis. This test looks for mutations in the BCR-ABL1 gene that may cause certain tyrosine kinase inhibitors (TKIs) that treat Ph+ CML in chronic phase to stop working.

 

Icon of magnifying glass

Identifying the T315I gene mutation

 

There are a number of different gene mutations that can occur in Ph+ CML in chronic phase, including a mutation called T315I. The only way to determine if you have a mutation is to undergo a BCR-ABL1 kinase domain mutation analysis. If this test shows that you have developed the T315I mutation, your doctor may consider whether to change your medication. 

SCEMBLIX is approved to treat Ph+ CML in chronic phase for those with the T315I mutation. 

 

Learn more about SCEMBLIX

 

Icon of question mark inside word balloon

Can you become resistant to your medication?

 

Over time, some people may stop responding to their medication for Ph+ CML in chronic phase. This may be caused by a gene mutation. If you aren’t seeing the results you had hoped for, ask your doctor if you should be tested for a gene mutation.

Important Safety Information

Before taking SCEMBLIX, tell your doctor about all your medical conditions, including if you:

  • have a history of inflammation of your pancreas (pancreatitis)
  • have a history of heart problems or blood clots in your arteries and veins (types of blood vessels)
  • are pregnant or plan to become pregnant. SCEMBLIX can harm your unborn baby ...

Approved Uses

SCEMBLIX is a prescription medicine used to treat adults with:

  • Philadelphia chromosome–positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with 2 or more tyrosine kinase inhibitors (TKIs)
  • Ph+ CML in CP with the T315I mutation ...
Click or scroll to see IMPORTANT SAFETY INFORMATION AND APPROVED USES